A method is described for exfoliating a microcrystal of an anthracene derivative by irradiation with short pulses of light having a wavelength of 220-420 nm. The irradiation induces a cis-trans isomerization of the anthracene derivative in a part of the microcrystal, which leads to the separation of an outer layer having a thickness of 200-600 nm. The exfoliated microcrystal may be irradiated again with pulses of light of a same or different wavelength.

A method is described for exfoliating a microcrystal of an anthracene derivative by irradiation with short pulses of light having a wavelength of 220-420 nm. The irradiation induces a cis-trans isomerization of the anthracene derivative in a part of the microcrystal, which leads to the separation of an outer layer having a thickness of 200-600 nm. The exfoliated microcrystal may be irradiated again with pulses of light of a same or different wavelength.

Provided are compositions and methods for visualizing the skeletal tissues of a biological specimen, comprising treating the specimen with a calcium chelating agent, a staining solution, and a clearing solution.

Provided are compositions and methods for visualizing the skeletal tissues of a biological specimen, comprising treating the specimen with a calcium chelating agent, a staining solution, and a clearing solution.

The present invention relates to the use of aromatic boronic acid or borinic acid derivatives in organic electronic devices, in particular electroluminescent devices.

The present invention relates to the use of aromatic boronic acid or borinic acid derivatives in organic electronic devices, in particular electroluminescent devices.

The present invention relates to an inorganic-organic hybrid compound as ionic compound, composed of an inorganic cation and of an organic active ingredient anion and also, optionally, of an organic fluorescent dye anion.

There is disclosed a compound, a pharmaceutical composition and a method of treatment using a pharmaceutical composition comprising a tethering moiety that is capable of binding to a macrophage migration inhibitory factor (MIF) polypeptide, optionally linked to a linker moiety and further covalently bound to a drug moiety or imaging agent. More specifically, there is disclosed a genus of affinity-tethering moieties covalently bound to a drug moiety or imaging agent either directly or optionally via a linker moiety to covalently link the tethering moiety to a drug moiety. Without being bound by theory, the disclosed pharmaceutical compounds are targeted to cancer cells or immune cells via an affinity-tethering moiety that hitch-hikes to or into its target cell while bound to endogenous MIF.